Hey Green - I was also irritated about the delay, particularly when it looked like that the trial would be fully enrolled by mid-year. but it looks like that they increased the enrolment to 171 patients from the original 154 targeted. the announcement is good in that they allocated 33 patients with PD-L1 less than 1 to cohort B.
What is annoying is why didn't IMM tell shareholders that. A further expansion of the trial is obviously a good thing, with more data to help support approval (Marc has previously said that if the data is compelling IMM will go to the FDA to seek approval based on these results).
Hey Green - I was also irritated about the delay, particularly...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $584.0M | |||
| Open | High | Low | Value | Volume |
| 41.0¢ | 41.0¢ | 40.5¢ | $123.5K | 301.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 50274 | 40.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 41.0¢ | 33157 | 2 |
View Market Depth
| Last trade - 10.32am 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
41.0¢ |
Change
0.000 ( 2.04 %) |
||||
| Open | High | Low | Volume | ||
| 41.0¢ | 41.5¢ | 40.5¢ | 64869 | ||
| Last updated 10.51am 14/06/2024 ? | |||||
| IMM (ASX) Chart |